Sanofi Expands Vaccine Pipeline with New Acquisition

Sanofi strengthens its pharmaceutical portfolio; the Vicebio acquisition increases the ability to develop respiratory vaccines.

Sanofi, the giant French pharmaceutical company, has just made its purchase of Vicebio Ltd., a previously unknown company, acquiring an early-stage blend vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). The distribution strengthens the strategy of the company, Sanofi, to increase its presence in the global pharmaceutical and vaccine innovation environment.

This is because the Molecular Clamp technology of Vicebio will ensure that Sanofi can design and develop new vaccines with advanced technology, which will enable it to have a diversified portfolio based on having a non-mRNA vaccine product. The acquisition gives the company more strength in its respiratory vaccine pipeline and improves physician and patient selection regarding the treatment of RSV and HMPV infections.

Sanofi observed that the acquisition of the vaccine will support the current respiratory products and complies with the long-term pharmaceutical research priorities of viral diseases with high burden.

Simultaneously, Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria (CSU) was just recently endorsed by the European Commission for Sanofi to treat patients aged 12 years or older who do not respond to conventional antihistamines. Through such permission, Dupixent is now a first-line, targeted treatment for qualified CSU patients, which stands to enhance the pharmaceutical leadership of Sanofi in the immunological context.

The joint changes reinforce the idea that Sanofi is in a more powerful role within the pharmaceutical industry, referencing the constant investments in both developmental therapies and next-generation vaccines.